EnVivo Pharmaceuticals, Progress on Major Drug Program Focusing on Alzheimer’s Diseases

October 17, 2007 - EnVivo Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs for neurodegenerative diseases, announced progress on several key programs for addressing Alzheimer’s*, Schizophrenia and Huntington’s diseases... The company believes that this lead compound represents one of the first highly potent, orally bio-available and brain-permeable HDAC inhibitors for neuro-degenerative diseases. HDAC inhibitors hold promise for treating the cognitive deficits of several diseases including Alzheimer’s disease... EnVivo's Press Release-

Memory Pharmaceuticals, Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease

Oct. 15 , 2007 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced top-line data from the multi-center, randomized, double-blind, placebo-controlled Phase 2a study of MEM 1003, a neuronal L-type calcium channel modulator, in Alzheimer's disease.The trial enrolled 183 subjects with mild to moderate Alzheimer's disease at over 40 centers in the United States and included monotherapy subjects and subjects on stable doses of cholinesterase inhibitors. The trial failed to meet its primary endpoint, which was a twelve-week mean change in the Alzheimer's disease Assessment Scale* -- Cognitive subscale (ADAS-cog) score in the overall population. ... Memory Pharmaceuticals' Press Release-

Satoris and First Blood Test to Diagnose Alzheimer's Disease

October 15, 2007 - — A team of international researchers reported they have identified a group of cell-signaling proteins found in blood that serve as a unique “voiceprint” that can not only be used to diagnose Alzheimer’s disease*, but also classify and predict presymptomatic individuals who will eventually develop the memory-robbing disorder. The study describing the new test appears in this week’s online version of the scientific journal, Nature Medicine. “Our technology enables us to ‘listen’ to the chatter of cells communicating with each other and determine if there’s anything abnormal,” said Tony Wyss-Coray, Ph.D., a lead scientist in the study, and a co-founder of San Francisco-based Satoris Inc. ... Satoris ' Press Release-

AlzPosition, Alzheimer and Treatments blog

The aim of the Blog "AlzPosition" is to share information found in life sciences companies websites which could be interesting to follow pharmaceuticals, treatments, diagnostic tests, clinical trials about Alzheimer treatments.